

*Please find detailed revenue data by segment from Johnson & Johnson's (J&J) full year 2024 financials and do not use XBRL data.*

Based on my research, I now have comprehensive information about Johnson & Johnson's 2024 full-year revenue data by segment. Let me create a detailed summary of their revenue breakdown.

### **Johnson & Johnson 2024 Full-Year Revenue Data by Segment**

Based on J&J's 2024 annual financial results, here is the detailed revenue breakdown by business segment:

#### **Total Company Revenue**

- **Total Revenue:** \$88.8 billion (4.3% growth vs. 2023)
- **Operational Growth:** 5.9% (excluding currency impact)
- **Adjusted Operational Growth:** 5.4% (excluding acquisitions/divestitures and currency)

#### **Primary Business Segments**

##### **1. Innovative Medicine (Pharmaceutical)**

- **Total Revenue:** \$56.964 billion (4.0% reported growth vs. 2023)
- **Operational Growth:** 5.7% (excluding currency)
- **Adjusted Operational Growth:** 5.8% (excluding acquisitions/divestitures and currency)
- **Excluding COVID-19 Vaccine Growth:** 7.5%

#### **Key Therapeutic Areas within Innovative Medicine:**

##### **Oncology (Leading growth driver)**

- Major products driving growth:
  - **DARZALEX** (daratumumab) - Multiple myeloma treatment, exceeded \$3 billion in Q4 alone (22% growth)
  - **ERLEADA** (apalutamide) - Prostate cancer treatment
  - **CARVYKTI** (ciltacabtagene autoleucel) - CAR-T therapy for multiple myeloma, approaching \$1 billion annually
  - **TECVAYLI** (teclistamab-cqyv) - Multiple myeloma treatment
  - **TALVEY** (talquetamab-tgvs) - Multiple myeloma treatment
  - Other Oncology products

##### **Immunology**

- Major products:

- **STELARA** (ustekinumab) - Facing biosimilar competition, declined 15% in Q4 to \$2.3 billion
- **TREMFYA** (guselkumab) - Growing, including new IBD indication
- **REMICADE** (infliximab) - Declining due to biosimilar competition
- **SIMPONI/SIMPONI ARIA** (golimumab)

## Neuroscience

- Major products:
  - **SPRAVATO** (esketamine) - Treatment-resistant depression, strong growth
  - **CONCERTA** (methylphenidate) - ADHD treatment
  - **INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA** - Antipsychotic medications

## Infectious Diseases

- **COVID-19 Vaccine** - Declining sales
- **HIV portfolio** including EDURANT, PREZISTA, PREZCOBIX, REZOLSTA, SYMTUZA

## Pulmonary Hypertension

- **OPSUMIT** (macitentan)
- **UPTRAVI** (selexipag)

## Cardiovascular & Metabolism

- **XARELTO** (rivaroxaban) - Anticoagulant

## 2. MedTech (Medical Devices)

- **Total Revenue:** \$31.857 billion (4.8% reported growth vs. 2023)
- **Operational Growth:** 6.2% (excluding currency)
- **Adjusted Operational Growth:** 4.7% (excluding acquisitions/divestitures and currency)
- **Net acquisitions/divestitures impact:** +1.5%

## Key Categories within MedTech:

### Cardiovascular (formerly Interventional Solutions)

- **Electrophysiology products** (Biosense Webster) - Strong growth
- **Abiomed** (acquired December 2022) - Heart recovery portfolio including Impella devices
- **Shockwave Medical** (acquired 2024) - Intravascular lithotripsy technology
- **V-Wave** (acquired Q4 2024) - Minimally invasive interatrial shunt

- **Cerenovus** - Neurovascular care for stroke treatment

#### **Orthopaedics (DePuy Synthes)**

- Hip replacement systems
- Knee replacement systems
- Trauma products
- Spine, Sports & Other products

#### **Surgery (Ethicon)**

- **Advanced Surgery** technologies
- **General Surgery** - Strong growth from wound closure products
- **Mentor** - Breast aesthetics solutions
- **Acclarent** - Ear, Nose and Throat procedures

#### **Vision (Johnson & Johnson Vision)**

- **Contact Lenses** - ACUVUE brand products, including new ACUVUE OASYS MAX 1-Day
- **Surgical Vision** - TECNIS intraocular lenses for cataract surgery

#### **Geographic Revenue Breakdown**

##### **Full Year 2024:**

- **United States:** \$50.3 billion (8.3% growth)
- **International:** \$38.5 billion (-0.5% reported, +2.9% operational)

##### **Q4 2024:**

- **United States:** \$13.2 billion (10.0% growth)
- **International:** \$9.3 billion (-0.7% reported, +2.5% operational)

#### **Key Growth Drivers for 2024:**

1. **Oncology portfolio**, particularly DARZALEX, ERLEADA, and CARVYKTI
2. **Neuroscience** growth from SPRAVATO
3. **Cardiovascular devices**, especially electrophysiology and Abiomed products
4. **Surgical products**, particularly wound closure technologies
5. **New product launches** across both segments

#### **Notable Headwinds:**

1. **STELARA biosimilar competition** beginning in 2024

2. **COVID-19 vaccine revenue decline**
3. **Currency translation impact** of -1.6% on total revenue
4. **Generic/biosimilar competition** affecting older products like REMICADE

This data reflects J&J's transition to a focused healthcare company following the spin-off of its Consumer Health business (Kenvue) in 2023, with strong performance across both pharmaceutical and medical technology segments.

Please find detailed revenue data by segment from Johnson & Johnson's (J&J) full year 2024 financials and use XBRL data thru the mcp server.

I've successfully extracted and analyzed detailed revenue data from Johnson & Johnson's 2024 financials using the XBRL data server. Here are the key findings:

### Summary of J&J's 2024 Revenue Performance:

**Total Revenue: \$88.821 billion**

The company operates through two main segments:

**1. Innovative Medicine (Pharmaceuticals): \$56.964 billion (64.1%)**

- Led by Oncology (\$20.8B), Immunology (\$17.8B), and Neuroscience (\$7.1B)
- Top products include DARZALEX (\$11.7B), STELARA (\$10.4B), and INVEGA SUSTENNA family (\$4.2B)

**2. MedTech (Medical Devices): \$31.857 billion (35.9%)**

- Balanced across Surgery (\$9.8B), Orthopedics (\$9.2B), Cardiovascular (\$7.7B), and Vision (\$5.1B)
- Strong performance in Electrophysiology (\$5.3B) and contributions from recent acquisitions like Abiomed (\$1.5B)

The analysis reveals J&J's diversified portfolio strength, with roughly balanced geographic exposure between the US (56.6%) and international markets (43.4%). The pharmaceutical business continues to drive growth while the medical device segment provides stability and diversification.

Would you like me to dive deeper into any specific segment, product line, or provide comparative analysis with previous years?

## Johnson & Johnson 2024 Revenue Analysis by Segment

### Executive Summary

**Total Revenue: \$88.821 billion** (Fiscal Year 2024)

Johnson & Johnson reported strong revenue performance across its two primary operating segments, with Innovative Medicine continuing to drive the majority of revenue growth.

---

### Primary Operating Segments

#### 1. Innovative Medicine (Pharmaceutical)

- **Total Revenue: \$56.964 billion (64.1% of total revenue)**
- **US Revenue: \$33.970 billion**

- **International Revenue: \$22.994 billion**

**Key Therapeutic Areas within Innovative Medicine:**

**Oncology - \$20.781 billion**

- DARZALEX: \$11.670 billion
- Erleada: \$2.999 billion
- IMBRUVICA: \$3.038 billion
- CARVYKTI: \$963 million
- TECVAYLI: \$549 million
- ZYTIGA: \$631 million
- Other Oncology: \$931 million

**Immunology - \$17.828 billion**

- STELARA: \$10.361 billion
- TREMFYA: \$3.670 billion
- SIMPONI/SIMPONI ARIA: \$2.190 billion
- REMICADE: \$1.605 billion
- Other Immunology: \$3 million

**Neuroscience - \$7.115 billion**

- INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA: \$4.222 billion
- SPRAVATO: \$1.077 billion
- CONCERTA: \$641 million
- Other Neuroscience: \$1.175 billion

**Pulmonary Hypertension - \$4.282 billion**

- OPSUMIT: \$2.184 billion
- UPTRAVI: \$1.817 billion
- Other Pulmonary Hypertension: \$281 million

**Cardiovascular/Metabolism/Other - \$3.562 billion**

- XARELTO: \$2.373 billion
- Other: \$1.189 billion

**Infectious Diseases - \$3.396 billion**

- PREZCOBIX/REZOLSTA/SYMTUZA: \$1.712 billion
- EDURANT: \$1.272 billion
- COVID-19 products: \$198 million
- Other Infectious Diseases: \$214 million

## **2. MedTech (Medical Devices)**

- **Total Revenue: \$31.857 billion (35.9% of total revenue)**
- **US Revenue: \$16.332 billion**
- **International Revenue: \$15.525 billion**

### **Key Product Categories within MedTech:**

#### **Surgery - \$9.845 billion**

- Advanced Surgery: \$4.488 billion
- General Surgery: \$5.358 billion

#### **Orthopedics - \$9.158 billion**

- Knees: \$1.545 billion
- Hips: \$1.638 billion
- Trauma: \$3.049 billion
- Spine/Sports/Other: \$2.926 billion

#### **Cardiovascular - \$7.707 billion**

- Electrophysiology: \$5.267 billion
- Abiomed: \$1.496 billion
- Shockwave Medical: \$564 million
- Other Cardiovascular: \$380 million

#### **Vision - \$5.146 billion**

- Contact Lenses/Other: \$3.733 billion
- Surgical Vision: \$1.413 billion

---

## **Geographic Revenue Distribution**

### **By Region:**

- **United States: \$50.302 billion (56.6%)**

- **International:** \$38.519 billion (43.4%)
    - Europe: \$20.212 billion (22.7%)
    - Asia Pacific/Africa: \$13.593 billion (15.3%)
    - Western Hemisphere (excluding US): \$4.714 billion (5.3%)
- 

## Key Performance Insights

### Innovative Medicine Highlights:

- **Oncology** remains the largest therapeutic area, representing 36.5% of Innovative Medicine revenue
- **DARZALEX** is J&J's top product with nearly \$12 billion in sales
- **STELARA** continues strong performance at over \$10 billion
- Strong growth in newer products like **CARVYKTI** and **TECVAYLI**

### MedTech Highlights:

- Balanced portfolio across four major categories
- **Surgery** is the largest MedTech segment at nearly \$10 billion
- **Electrophysiology** within Cardiovascular is a standout performer at \$5.3 billion
- **Abiomed** acquisition contributing \$1.5 billion in cardiovascular revenue

### Geographic Balance:

- Strong presence in both US and international markets
  - US represents majority of revenue but international markets provide significant diversification
  - Europe remains the largest international region
- 

## Data Source

*Analysis based on XBRL financial data from Johnson & Johnson's 2024 Form 10-K filing (Report ID: 806818)*